Page 115 - 《中国药房》2026年7期

替瑞奇珠单抗与司库奇尤单抗治疗中重度斑块状银屑病的疗效

和安全性对比
Δ

1＊
陈 宁 ，冯要菊 ，丁 昱（1.南阳医学高等专科学校第一附属医院皮肤科，河南 南阳 473000；2.南阳医学
1
2
高等专科学校第一附属医院风湿科，河南 南阳 473000）
中图分类号 R969.4；R758.63 文献标志码 A 文章编号 1001-0408（2026）07-0933-05
DOI 10.6039/j.issn.1001-0408.2026.07.18

摘 要 目的 比较替瑞奇珠单抗与司库奇尤单抗治疗中重度斑块状银屑病的有效性及安全性。方法 回顾性分析2024年1月至
2025年4月在南阳医学高等专科学校第一附属医院接受治疗的141例中重度斑块状银屑病患者，根据治疗方案分为替瑞奇珠单
抗组（61例）和司库奇尤单抗组（80例）。比较两组患者PASI 75、PASI 90、PASI 100达标率，治疗前后银屑病面积与严重程度指数
（PASI）和皮肤病生活质量指数（DLQI）评分、皮肤屏障功能（皮脂含量、角质层含水量）、炎症因子[白细胞介素17（IL-17）、肿瘤坏
死因子α（TNF-α）、IL-23]水平，以及治疗期间不良反应发生率。结果 经过12周治疗后，替瑞奇珠单抗组患者的PASI 75、PASI 90
及PASI 100达标率均显著高于司库奇尤单抗组（P＜0.05）。治疗后，两组患者的PASI、DLQI评分以及IL-17、TNF-α、IL-23水平均
较同组治疗前显著降低，皮脂含量和角质层含水量均较同组治疗前显著升高（P＜0.05），且替瑞奇珠单抗组均优于司库奇尤单抗
组（P＜0.05）。替瑞奇珠单抗组患者的总体不良反应发生率显著低于司库奇尤单抗组（P＜0.05）。结论 与司库奇尤单抗相比，替
瑞奇珠单抗治疗中重度斑块状银屑病的疗效更优，在改善症状、提升皮肤屏障功能、降低炎症因子水平方面效果更显著，且安全性
更好。
关键词 替瑞奇珠单抗；司库奇尤单抗；中重度斑块状银屑病；有效性；安全性；生物制剂

Comparison of efficacy and safety between tildrakizumab and secukinumab in the treatment of moderate-
to-severe plaque psoriasis
CHEN Ning ，FENG Yaoju ，DING Yu （1. Dept. of Dermatology，the First Affiliated Hospital of Nanyang
2
1
1
Medical College，Henan Nanyang 473000，China；2. Dept. of Rheumatology，the First Affiliated Hospital of
Nanyang Medical College，Henan Nanyang 473000，China）
ABSTRACT OBJECTIVE To compare the efficacy and safety of tildrakizumab versus secukinumab in the treatment of moderate-
to-severe plaque psoriasis. METHODS A retrospective analysis was conducted on 141 patients with moderate-to-severe plaque
psoriasis treated at the First Affiliated Hospital of Nanyang Medical College from January 2024 to April 2025. According to the
treatment regimen，the patients were divided into tildrakizumab group （n＝61） and secukinumab group （n＝80）. The PASI 75，PASI
90，and PASI 100 response rates， the Psoriasis Area and Severity Index （PASI） and Dermatology Life Quality Index （DLQI）
scores， skin barrier function （sebum content and stratum corneum water content）， inflammatory factor levels [interleukin-17 （IL-
17）， tumor necrosis factor-α （TNF-α）， and IL-23] before and after treatment， and the incidence of adverse drug reactions during
treatment were compared between the two groups. RESULTS After 12 weeks of treatment， the PASI 75， PASI 90， and PASI 100
response rates in the tildrakizumab group were significantly higher than those in the secukinumab group （P＜0.05）. After treatment，
PASI and DLQI scores as well as serum levels of IL-17， TNF-α， and IL-23 in both groups were significantly reduced compared to
before treatment in the same group； sebum content and stratum corneum water content were significantly increased compared to
before treatment in the same group （P＜0.05）； the tildrakizumab group showed better results than the secukinumab group （P＜
0.05）. The overall incidence of adverse drug reactions was also significantly lower in the tildrakizumab group compared with the
secukinumab group （P＜0.05）. CONCLUSIONS Compared with secukinumab， tildrakizumab demonstrates superior efficacy in the
treatment of moderate-to-severe plaque psoriasis， providing improved symptom relief， enhanced skin barrier function， reduced
levels of inflammatory factors， and higher safety.
KEYWORDS tildrakizumab； secukinumab； moderate-to-severe plaque psoriasis； efficacy； safety； biological agent

Δ 基金项目 河南省自然科学基金项目（No.222300420480）
银屑病是一种以 T 细胞介导为核心的慢性自身免
＊第一作者 主治医师。研究方向：皮肤病。E-mail：chen_n1982@
163.com 疫性皮肤病，其中斑块状银屑病是最为常见的亚型，约

中国药房 2026年第37卷第7期 China Pharmacy 2026 Vol. 37 No. 7 · 933 ·